A corporate blog from Genetic Leap, a company using AI and computational platforms for genetically-defined drug target selection and RNA-targeted therapeutics. Posts cover company news, conference appearances and technical perspectives on experimental validation of AI-driven predictions.
Website: https://blog.genetic-leap.com/
Long-form essays examining the scientific claims and limits of biological research, especially organoids in drug discovery, disease modeling, and Alzheimer's research. Readers get critical, detailed analysis of where lab models succeed, fail, and get overhyped, plus updates from the author's work on AI and health.
A personal-essay-driven newsletter on data, companies and ideas at the frontier of biology, covering topics like AI in drug discovery, the economics of pharma R&D and founder stories. Readers get long-form analysis of the biotech landscape, investments and historical context of life sciences.
A daily brief covering AI agents in biomedical and drug discovery, pairing short news items with 'why it matters' commentary on each. The sample issues cover OpenAI's acquisition of a drug-development agent startup, lab-designed binders and benchmark studies of agent reliability.
Peter Diamandis-style essays on exponential technology, covering AI's effect on biotech, business moats, and education reform, often promoting his investments and Abundance360 community. Readers get big-picture futurist commentary with investment and entrepreneurial angles.
One short email a week with hand-picked newsletters from the index. Free, no spam, unsubscribe anytime.
